Table 1 Clinical characteristics of this T-ALL cohort.
T-ALL | ||
|---|---|---|
(n = 64) | ||
n | % | |
Gender | ||
Male | 45 | 70.3 |
Female | 19 | 29.7 |
Age (years) | ||
1–9.9 | 24 | 37.5 |
≥ 10 | 40 | 62.5 |
WBC (× 109/L) | ||
< 50 | 27 | 42.2 |
≥ 50 | 36 | 56.3 |
No data | 1 | 1.6 |
Protocol | ||
TPOG 2002 | 49 | 76.6 |
TPOG 2013 | 15 | 23.4 |
Early treatment response# | ||
MRD positive | 4 | 6.3 |
MRD negative | 10 | 15.6 |
No data | 50 | 78.1 |
Subtype | ||
TAL1 | 12 | 19.4 |
TAL2 | 4 | 6.3 |
TLX3 | 1 | 1.6 |
LMO1/LMO2 | 1 | 1.6 |
LMO2/LYL1 | 2 | 3.1 |
NKX2-1 | 2 | 3.1 |
HOXA | 6 | 9.4 |
Other | 17 | 26.6 |
No data | 19 | 30.7 |
Early T-cell precursor | ||
Positive | 7 | 10.9 |
Negative | 29 | 45.3 |
No data | 28 | 43.8 |
TRG status | ||
ABD | 12 | 18.8 |
Deletion | 24 | 37.5 |
No data | 28 | 43.8 |
CNS Leukemia | ||
Positive | 22 | 34.4 |
Negative | 39 | 60.9 |
No data | 3 | 4.7 |
Bone marrow transplantation | ||
Total patients | 12 | 18.8 |
Living | 5 | 7.8 |
Deceased | 7 | 10.9 |
Outcome | ||
Death | 24 | 37.5 |
Relapse | 28 | 43.8 |
No event | 36 | 56.3 |
